By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera has accepted Pfizer's $10 billion acquisition ...

Under the terms of the cash deal, Pfizer will pay $65.60 a share upfront and a contingent value right worth up to $20.65 a ...

By Rishabh Jaiswal and Sabrina Valle (Reuters) -Obesity drug developer Metsera said on Friday that it had accepted Pfizer's ...

Earlier this year, Pfizer shelved a clinical trial for its own weight-loss drug candidate amid safety concerns and shifted ...

Pfizer will pay $86.25 a share in cash, a premium of 3.69% to Metsera's Friday close, according to Metsera's statement. The ...

The announcement of the deal signaled an end to the bidding war for Metsera between Pfizer and Novo Nordisk, the Danish maker ...

The Metsera deal is about winning the obesity drugs' market that’s expected to reach US$100 billion by 2030. Read more at ...

Pfizer Inc. has agreed to buy Metsera Inc. for $10 billion, surpassing Novo Nordisk in a competitive bidding war. Details of ...

Metsera, an obesity drug developer, has accepted a $10 billion acquisition offer from pharmaceutical giant Pfizer, potentially concluding a bidding war with Novo Nordisk.

Metsera said that Pfizer will pay up to US$86.25 a share, including US$65.60 a share in cash initially, plus potential additional payments of up to US$20.65 a share for hitting certain milestones.

After a bidding war erupted between Pfizer and Novo Nordisk over the fledgling obesity drug maker, Metsera decided to side with its original suitor.